Alligator Bioscience and Amphera have announce the successful dosing of the last patient in the REACTIVE-2 Phase 1 trial evaluating mitazalimab in combination with MesoPher in patients with metastatic pancreatic cancer.
The open-label, single-center Phase 1 dose finding study is assessing the safety and efficacy of Alligator’s lead asset mitazalimab, in combination with Amphera’s cancer vaccine MesoPher, in patients with metastatic pancreatic cancer after standard of care treatment with mFOLFIRINOX. REACTIVE-2 is an investigator-sponsored trial being performed at Erasmus Medical Center in Rotterdam.
“Our CD40 agonist and Amphera’s cancer vaccine have both shown great promise in their own separate clinical studies emphasizing the crucial role of dendritic cells and other myeloid cells in immune response to pancreatic cancer,” says Søren Bregenholt, CEO of Alligator Bioscience. “We have high hopes that a combination of mitazalimab and MesoPher can drive clinically meaningful anti-tumor immunity and potentially offer a new therapeutic option in this hard to treat patient population.”
Preliminary results are expected in Q4 2023.
Photo of Søren Bregenholt: Alligator
